14:09 Wed 23 Dec 2020
Destiny Pharma PLC - Grant of share options
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of share options
Destiny Pharma plc (AIM: DEST, "the Company") a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces that it has granted options ("Options") over 1,985,620 new ordinary shares of
Name |
Position |
Options Issued 2018 LTIP scheme |
Options Issued 2020 LTIP scheme |
Total Options Held Post Issue |
|
Chief Executive Officer |
205,695 |
353,692 |
1,103,692
|
|
Chief Financial Officer
Chief Scientific Officer
Chief Medical Officer and PDMR |
125,000
125,000
115,000 |
261,538
240,511
219,184 |
661,538
1,130,905 449,184
|
The first tranche of Option awards have been made under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on
The second tranche of Options represent awards granted under the new Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on
Enquiries:
Destiny Pharma plc |
+44 (0) 1273 704 440 |
|
|
finnCap Limited - Nominated Adviser and Joint Broker |
+44 (0) 20 7220 0500 |
|
|
WG Partners LLP - Joint Broker |
+44 (0) 20 3705 9330 |
|
|
Optimum Strategic Communications |
+44 (0) 203 174 1789 |
Mary Clark /
|
|
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which is in a Phase 2b clinical trial targeting the prevention of post-surgical Staphylococcal hospital including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information, please visit https://www.destinypharma.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
|
2. |
Reason for the Notification |
|
a) |
Position/status |
Chief Executive Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Destiny Pharma plc |
b) |
LEI |
213800O9WH9Z38EHAC95 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the Financial instrument, type of instrument |
Grant of award of options over ordinary shares of
|
Identification code |
DEST GB00BDHSP575 |
|
b) |
Nature of the transaction |
Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) |
Price(s) and volume(s) |
559,387 Ordinary Shares |
d) |
Aggregated information: Aggregated volume Price |
See 4c) above
|
e) |
Date of the transaction |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
|
2. |
Reason for the Notification |
|
a) |
Position/status |
Chief Financial Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Destiny Pharma plc |
b) |
LEI |
213800O9WH9Z38EHAC95 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the Financial instrument, type of instrument |
Grant of award of options over ordinary shares of
|
Identification code |
DEST GB00BDHSP575 |
|
b) |
Nature of the transaction |
Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) |
Price(s) and volume(s) |
386,538 Ordinary Shares |
d) |
Aggregated information: Aggregated volume Price |
See 4c) above
|
e) |
Date of the transaction |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
|
2. |
Reason for the Notification |
|
a) |
Position/status |
Chief Scientific Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Destiny Pharma plc |
b) |
LEI |
213800O9WH9Z38EHAC95 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the Financial instrument, type of instrument |
Grant of award of options over ordinary shares of
|
Identification code |
DEST GB00BDHSP575 |
|
b) |
Nature of the transaction |
Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) |
Price(s) and volume(s) |
365,511 Ordinary Shares |
d) |
Aggregated information: Aggregated volume Price |
See 4c) above
|
e) |
Date of the transaction |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
|
2. |
Reason for the Notification |
|
a) |
Position/status |
Chief Medical Officer |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Destiny Pharma plc |
b) |
LEI |
213800O9WH9Z38EHAC95 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the Financial instrument, type of instrument |
Grant of award of options over ordinary shares of
|
Identification code |
DEST GB00BDHSP575 |
|
b) |
Nature of the transaction |
Grant of award of options over Ordinary Shares under the 2018 Destiny Pharma plc Long Term Incentive Plan and 2020 Destiny Pharma plc Long Term Incentive Plan. |
c) |
Price(s) and volume(s) |
334,184 Ordinary Shares |
d) |
Aggregated information: Aggregated volume Price |
See 4c) above
|
e) |
Date of the transaction |
|
f) |
Place of the transaction |
London Stock Exchange, AIM Market |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE